올리고뉴클레오티드 합성 시약 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Oligonucleotide Synthesis Reagents Market Summary

The global oligonucleotide synthesis reagents market size was estimated at USD 723.3 million in 2025 and is projected to reach USD 1751.3 million by 2033, growing at a CAGR of 11.9% from 2026 to 2033. The growth is driven by increasing demand for oligonucleotide-based therapeutics, expanding applications in diagnostics and genomics, and advancements in DNA/RNA synthesis technologies.

Rapid growth of nucleic acid-based therapeutics

The rapid growth of nucleic acid-based therapeutics is a key driver of the oligonucleotide synthesis reagents market, as these therapies depend on synthetic oligonucleotides as core components. Modalities such as siRNA, antisense oligonucleotides (ASOs), CRISPR-based gene editing, and mRNA platforms are increasingly targeting previously undruggable pathways, with multiple approved therapies and a growing pipeline across oncology, rare genetic disorders, and infectious diseases. This expansion is driving demand for high-quality oligonucleotide production and, consequently, increasing consumption of synthesis reagents from research through commercialization.

Global Oligonucleotide Synthesis Reagents Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the oligonucleotide synthesis reagents market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Core synthesis reagents
• Process reagents
• Modification reagents
• Purification-related reagents
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• PCR primers
• PCR assays and panels
• Sequencing
• DNA microarrays
• Fluorescence In Situ Hybridization (FISH)
• Antisense oligonucleotides
• Other applications
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & research institutes
• Diagnostic laboratories
• Pharmaceutical and biotechnology companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Oligonucleotide Synthesis Reagents Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rapid growth of nucleic acid-based therapeutics
    • 3.2.1.2. Expansion of molecular diagnostics
    • 3.2.1.3. Advancements in synthesis technologies
    • 3.2.1.4. Expansion of genomics and genetic research
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of reagents and synthesis processes
    • 3.2.2.2. Complex and time-consuming synthesis procedures
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenge analysis
• 3.3. Case Study Insights
• 3.4. Oligonucleotide Synthesis Reagents Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTEL Analysis

Chapter 4. Oligonucleotide Synthesis Reagents Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Oligonucleotide Synthesis Reagents Market Product Movement Analysis
• 4.3. Global Oligonucleotide Synthesis Reagents Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Core synthesis reagents
  • 4.4.1. Core synthesis reagents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Process reagents
  • 4.5.1. Process reagents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Modification reagents
  • 4.6.1. Modification reagents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Purification-related reagents
  • 4.7.1. Purification-related reagents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Oligonucleotide Synthesis Reagents Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Oligonucleotide Synthesis Reagents Market Application Movement Analysis
• 5.3. Global Oligonucleotide Synthesis Reagents Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. PCR primers
  • 5.4.1. PCR primers market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. PCR assays and panels
  • 5.5.1. PCR assays and panels market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Sequencing
  • 5.6.1. Sequencing market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. DNA microarrays
  • 5.7.1. DNA microarrays market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Fluorescence In Situ Hybridization (FISH)
  • 5.8.1. Fluorescence In Situ Hybridization (FISH) market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Antisense oligonucleotides
  • 5.9.1. Antisense oligonucleotides market estimates and forecasts 2021 to 2033 (USD Million)
• 5.10. Other applications
  • 5.10.1. Other applications market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Oligonucleotide Synthesis Reagents Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Oligonucleotide Synthesis Reagents Market End Use Movement Analysis
• 6.3. Global Oligonucleotide Synthesis Reagents Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Academic & research institutes
  • 6.4.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Diagnostic laboratories
  • 6.5.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Pharmaceutical and biotechnology companies
  • 6.6.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Oligonucleotide Synthesis Reagents Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Danaher Corporation
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Tokyo Chemical Industry Pvt. Ltd.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Agilent Technologies, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Bio-Synthesis, Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Kaneka Eurogentec S.A.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. LGC Biosearch Technologies
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Biolegio
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Twist Bioscience
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives